MaxCyte, Inc. Filing of Form 10-Q (9104K)
May 10 2022 - 3:41AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 9104K
MaxCyte, Inc.
10 May 2022
MaxCyte announces filing of Form 10-Q for the quarterly period
ended March 31, 2022
GAITHERSBURG, MD, May 10, 2022 - MaxCyte, Inc., (NASDAQ: MXCT;
LSE: MXCT), a leading commercial cell engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization , today announced that
it has filed a Form 10-Q with the SEC for the quarterly period
ended March 31, 2022.
A copy of the Form 10-Q is available to view on the SEC's
website at www.sec.gov and has also been posted to the "SEC
filings" page of the Company's website,
https://investors.maxcyte.com/ .
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM) GTx(TM)
and VLx(TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
MaxCyte Contacts:
US IR Adviser +1 415-937-5400
Gilmartin Group ir@maxcyte.com
David Deuchler, CFA
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBKKBPPBKKPPD
(END) Dow Jones Newswires
May 10, 2022 03:41 ET (07:41 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Aug 2023 to Aug 2024